In Minnesota, health-related cannabis was authorized for use in 2014. From July 2015 to February 2019, our center certified 103 pediatric and young adult individuals for the use of health-related cannabis under the qualifying situations of cancer and therapy-associated symptoms. Right here, we offer a overview of the literature on health-related cannabis use in pediatric and young adult cancer individuals. We also offer demographic information on our individuals certified for health-related cannabis. The most prevalent diagnoses have been leukemia/lymphoma (36%), brain tumors (37%), and malignant strong tumors (26%). The most prevalent indications have been chemotherapy-associated nausea, discomfort, and cancer cachexia. The age variety at certification was 1.four-28.7 years (median 15.three years). The time from cancer diagnosis to certification ranged from .five-197 months (median eight.9 months). The majority (94%) have been certified in the course of their very first line of therapy. In the 32 individuals who died from recurrent or progressive cancer, the time from certification to death was 1.three-30.three months (median four.four years). Regardless of requesting certification, a subset (24%) in no way had health-related cannabis dispensed. In our encounter, pediatric and young adult oncology individuals are interested in health-related cannabis to aid handle therapy-associated symptoms. Ongoing evaluation of this information will recognize the therapeutic efficacy of health-related cannabis.
Copyright © 2018 Elsevier B.V. All rights reserved.
PMID: 31212902 PMCID: PMC6617193 DOI: 10.3390/youngsters6060079
Skrypek MM1, Bostrom BCtwo, Bendel AEthree.